Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell Ltd. - Ordinary Shares (GMDA)
Last gamida cell ltd. - ordinary shares earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge® (omidubicel-onlv) Preliminary data presented on GDA-201, Gamida Cell’s natural killer (NK) cell therapy candidate in ongoing Phase 1 study for non-Hodgkin lymphoma, show promising early evidence of anti-tumor activity BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Mar
Show less
Read more
Impact Snapshot
Event Time:
GMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMDA alerts
High impacting Gamida Cell Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GMDA
News
- Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewswire
- GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR® [Yahoo! Finance]Yahoo! Finance
- Gamida Cell Ltd. (NASDAQ: GMDA) had its "market perform" rating re-affirmed by analysts at JMP Securities.MarketBeat
- Gamida Cell Actively Pursuing Strategic Alternatives [Yahoo! Finance]Yahoo! Finance
GMDA
Earnings
- 11/14/23 - Beat
GMDA
Sec Filings
- 4/5/24 - Form 8-K/A
- 4/1/24 - Form SC
- 3/29/24 - Form 8-K/A
- GMDA's page on the SEC website